NETRIS PHARMA SELECTED BY THE EUROPEAN INNOVATION COUNCIL ACCELERATOR AMONG THE MOST INNOVATIVE STARTUPS AND SMES COMPANIES IN EUROPE !
The selected companies will receive grants and/or equity investments, depending on their needs, up to a maximum of EUR 17.5 million. They were selected following a rigorous process, introduced under Horizon Europe, involving an ideas screening stage, and full applications assessed by external experts and an interview with a jury of experienced investors and entrepreneurs.
The selected companies have a wide geographical spread spanning 21 countries, including seven from Horizon Europe “widening countries” that have lower levels of research and innovation performance. The selection also confirms the high demand for EIC equity investments with 65 of the 99 companies requesting equity investments of up to EUR 414 million (out of the total EUR 627 million). In most cases, the companies will receive the grant financing within the coming months, while the equity investment is likely to take longer as the arrangements for implementing EIC equity need to be re-established under Horizon Europe. This delay will also affect companies selected in the previous funding round.
For more information: https://eic.ec.europa.eu/news/largest-ever-funding-round-european-innovation-council-accelerator-99-innovative-companies-set-2021-12-16_en.